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Shu YuanAbstract
There is currently no effective treatment for the Ebola virus (EBOV) thus far. Most drugs and vaccines developed to
date have not yet been approved for human trials. Two FDA-approved c-AbI1 tyrosine kinase inhibitors Gleevec
and Tasigna block the release of viral particles; however, their clinical dosages are much lower than the dosages
required for effective EBOV suppression. An α-1,2-glucosidase inhibitor Miglustat has been shown to inhibit EBOV
particle assembly and secretion. Additionally, the estrogen receptor modulators Clomiphene and Toremifene
prevent membrane fusion of EBOV and 50-90% of treated mice survived after Clomiphene/Toremifene treatments.
However, the uptake efficiency of Clomiphene by oral administration is very low. Thus, I propose a hypothetical
treatment protocol to treat Ebola virus infection with a cumulative use of both Miglustat and Toremifene to inhibit
the virus effectively and synergistically. EBOV infection induces massive apoptosis of peripheral lymphocytes. Also,
cytolysis of endothelial cells triggers disseminated intravascular coagulation (DIC) and subsequent multiple organ
failures. Therefore, blood transfusions and active treatments with FDA-approved drugs to treat DIC are also
recommended.
Keywords: Ebola virus infection, Disseminated intravascular coagulation, Glycosylation inhibitors, Miglustat,
Niemann-Pick C1 inhibitors, ToremifeneMultilingual abstracts
Please see Additional file 1 for translations of the
abstract into the six official working languages of the
United Nations.Review
In the recent outbreak of the Ebola virus (EBOV) in
Africa, more than 20,000 people were infected causing
more than 8,000 deaths this year (recorded until January
14, 2015). No specific treatment for the Ebola virus is
available, as of yet. Vaccines have been recently developed
[1,2] and human trials are scheduled to begin shortly.
However, there is still a long way before these vaccines
can be applied clinically. Positively charged phosphorodia-
midate morpholino oligomers (PMOplus) are effective in
the treatment of EBOV [3]. BCX4430 is a type of adeno-
sine analogue, which can also inhibit viral replication [4].
TKM-Ebola, the most promising gene therapy agent, has
only recently entered phase I clinical trials [5]. Currently,Correspondence: roundtree318@hotmail.com
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unless otherwise stated.neither antibodies nor existing drugs can directly relieve
the hemorrhagic fever symptom, and they are usually inef-
fective when applied later than 4 days after infection
(interferon-α at day 1 post-infection combined with an
antibody mixture at the fourth day are also effective, but
not any later) [6]. Furthermore, most of these are newly
developed drugs (antibodies) without FDA approval and
treatment may not be economically feasible for thousands
of African patients (Figure 1 and Table 1).
Viral infection often leads to excessive host immune
responses, which may cause death. In this case, the body
attacks itself [7]. If the excessive immune response was
restrained, the virus could possibly be cleared later by
the body's immune mechanisms (if the virus is
recognizable by the human immune system), similar to
the influenza virus [7]. In the last year, I proposed an
“Avian Influenza Cocktail Therapy” (AICT) to control
excessive inflammation and inhibit viral replication [7].
Here I put forward a similar treatment protocol for
Ebola virus infection, which includes two suggestions:
(a) Combined inhibition of glycosylation of viral GP pro-
tein (by Miglustat, presumably) and EBOV intracellularan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart algorithm for the literature search.
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limit viral spread and force the virus to be exposed
under the monitoring of the host immune system; (b)
Blood transfusion which may control EBOV-induced
acute DIC, an excessive immune response.
Methods
For the purpose of this scoping review, I conducted a lit-
erature search of peer reviewed papers in electronic da-
tabases for the period up to December 2014. The
purpose of the search and literature review was to as-
semble published articles and reports associated with
this review, as well as to identify any drugs to treat
EBOV infection on any level (in-vitro cell culture, animal
models or non-human primates) and their limitations.
The three main databases used in the search procedure
were PubMed, ScienceDirect, and ISI Web of Science.
We employed the keywords: ‘Ebola’, ‘drug’, with or
without ‘FDA’. These keywords were entered into the
‘Title’, ‘Abstract’ and ‘Keywords’ fields in the databases.
Through this search, we obtained a total of 320 resultswithout the keyword ‘FDA’ and 20 results with the keyword
‘FDA’. These were screened for relevancy, resulting in a
total of 42 research papers without ‘FDA’ and 10 research
papers with ‘FDA’ which were analyzed for this review
(Figure 1). For each drug, its side-effects were further ex-
plored in the three main databases with the keyword ‘side
effect’ or ‘adverse effect’ and the drug’s name (Figure 1).
Results and discussion
Current drugs and treatments
Antiserum transfer
Levels of neutralizing antibodies are always low in
EBOV-infected patients, likely because of glycosylation
of the viral surface glycoprotein GP [8,9]. On the other
hand, GP glycosylation induces antibody-dependent viral
enhancement (see next section for details) [10,11].
Therefore, simple transfer of antiserum from convales-
cing patients did not protect recipient patients. On the
contrary, plasma or serum from convalescing patients
undesirably enhanced the infection of primate kidney
cells by the EBOV [10].
Table 1 Drugs for inhibiting EBOV replication






dosage ≥ concentration to
effective EBOV inhibition
Safety (side effects) References
EBOV antibodies No (in phase
I trial)
Yes Not available In assessing [1,2,6]
TIM-1 antibody No No Not available Not available [15,16]
PMOplus No Yes Not available Not available [3]
BCX4430 No Yes Not available Not available [4]
TKM-Ebola No (in phase
I trial)
Yes Not available In assessing [5]
Ouabain No No Not available Toxic in high levels [14]
Imatinib (Gleevec or Glivec) Yes No No A little [17]
Nilotinib (Tasigna) Yes No No A little [17]
Miglustat Yes Yes Yes (by oral admin.) A little [23]
Benzylpiperazine adamantane
diamide
No No Not available Not available [26]
Clomiphene (Androxal, Clomid
or Omifin)
Yes Yes Yes (by injection) A little [27,28]
Toremifene (Fareston or Acapodene) Yes Yes Yes (by oral admin.) A little [27,28]
Amiodarone (Cordarone, or Nexterone),
Dronedarone (Multaq) or Verapamil
(Calan or Isoptin)
Yes No Not available Risk of QT prolongation
(cardiotoxicity)
[27,29]
Amiloride (Midamor) Yes No Not available A little [30,31]
Chloroquine (Aralen) Yes No Ineffective for primates A little [32,33]
Favipiravir (Avigan) No Yes Suboptimal for primates A little [35]
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The innate immune reaction after EBOV infection is
characterized by a “cytokine storm,” with hypersecretion
of numerous proinflammatory cytokines, chemokines,
and growth factors, and by the noteworthy absence of
antiviral interferon-α2 [12]. Viral VP24 protein binds kar-
yopherin alpha nuclear transporters, inhibiting nuclear
import of the transcription factor STAT1, therefore pre-
venting interferon production [13]. However, a single
treatment with interferon cannot cure EBOV infection, al-
though interferon enhances the EBOV-specific adaptive
immune response as well as inhibits viral replication [6].
Recently, researchers identified several proteins which
interact with VP24 and found a small molecule inhibitor,
Ouabain, which can inhibit EBOV replication in human
lung cells [14]. However, Ouabain is not FDA-approved,
and may be toxic in high concentrations. Besides, there is
no experimental evidence for Ouabain in living animals
infected with EBOV available so far (Figure 2 and Table 1).Drugs targeting TIM-1
T-cell Ig and mucin domain 1 (TIM-1) protein is a
cellular receptor for EBOV [15]. TIM-1 and related PS-
binding proteins promote infection of diverse families ofenveloped viruses [16]. Therefore, a monoclonal antibody
against TIM-1 blocked EBOV binding and infection [15].
However, small molecules targeting TIM-1 have not yet
been developed (Figure 2).Drugs targeting c-AbI1
Two leukemia drugs, Gleevec (Imatinib) and Tasigna
(Nilotinib) lower the Ebola virus’ replication ability by
inhibiting c-AbI1 tyrosine kinase [17]. c-AbI1 is required
for tyrosine phosphorylation of the Ebola matrix protein
VP40, which is involved in the release of Ebola virus par-
ticles. Productive replication (TCID50) of the highly
pathogenic Ebola virus Zaire strain was inhibited by 20
μM Nilotinib by up to four orders of magnitude [17].
However, the plasma concentrations of Imatinib or
Nilotinib usually reached 2–3 μM at the normal dosages
[18,19]. Even at the maximal dosages (two times of the
normal dosage), the plasma concentrations (about 6 μM)
are still far below the concentration for effective EBOV
inhibition (20 μM) [17]. Besides, there is also no experi-
mental evidence with living animals showing clinical
validity to EBOV infection (Figure 2 and Table 1). Thus,
neither Imatinib nor Nilotinib are currently used for
EBOV therapy currently.
Figure 2 Model of the therapeutic mechanisms at the subcellular level: Drugs are shown with the stroke red color. EBOV, Ebola virus; L, viral RNA
polymerase L protein. In addition to the viral surface glycoprotein (GP trimer), EBOV directs the production of large quantities of a truncated
glycoprotein isoform (sGP dimer) that is secreted into the extracellular space. sGP can absorb anti-GP neutralizing antibodies (green ‘Y’) [9]. On
the other hand, another antibody against glycosylated GP peptides is generated (purple ‘Y’), which enhances virus infection. The complement
component C1q increases the likelihood of viral attachment to the cell surface [10,11]. Inhibition to GP glycans (dark-blue dot outside the GP
protein) may reduce this antibody-dependent enhancement (ADE) ideally. Miglustat is a clinically-approved glycosidase inhibitor. Three derivates
of Miglustat showed significant in-vitro antiviral activities against EBOV [23]. T-cell Ig and mucin domain 1 (TIM-1) and Niemann-Pick C1 (NPC1) are
cellular receptors for EBOV [15,25]. The membrane fusion mediated by EBOV glycoproteins and viral escape from the vesicular compartment
require the NPC1 protein [25]. Most NPC1 inhibitors are benzylpiperazine adamantane diamide derivates, non-FDA-approved drugs [26]. Recent
studies showed that Clomiphene and Toremifene are novel NPC1 inhibitors and act as potential inhibitors of EBOV [27,28]. Viral VP24 protein
inhibits nuclear import of the transcription factor STAT1, preventing interferon production [13]. Ouabain inhibits this process [14]. Two leukemia
drugs Gleevec and Tasigna lower Ebola virus replication by inhibiting c-AbI1 tyrosine kinase, which is required for the release of Ebola virus
particles [17].
Yuan Infectious Diseases of Poverty  (2015) 4:23 Page 4 of 10Glycosylation inhibitors
In addition to the viral surface glycoprotein (GP trimer),
EBOV directs the production of large quantities of a
truncated glycoprotein isoform (sGP dimer) that is se-
creted into the extracellular space. sGP can efficiently
compete for anti-GP antibodies and therefore absorb
anti-GP neutralizing antibodies [9]. The crystal structure
of sGP showed that the glycan cap surrounding EBOV
GP likely forms a shield that protects it from antigen-
antibody binding, which is central to its immune evasion
[8,20]. GP glycosylation inhibits neutralizing antibody
production. Subsequently, another antibody against glyco-
sylated GP peptides (the mucin-like domain) is generated,which enhances viral infection (infecting more endothelial
cells and inducing extensive endothelial cell death). Com-
plement component C1q enables binding between the
virus-antibody complex and C1q ligands on the cell
surface, promoting interaction between the virus and its
receptor. Binding of the virus via the C1q molecule
increases the likelihood of viral attachment to the cell sur-
face [10,11]. Inhibition of GP glycans would ideally reduce
this antibody-dependent enhancement (ADE).
The glycans that reside on the outside of GP are very
complex in nature [8]. Therefore, glycosidases (especially
the peptide-N-glycosidase) cannot reach the cleavage
site efficiently. To target GP we must find another way
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of now, Miglustat (N-butyldeoxynojirimycin, American
Actelion Pharms, for Gaucher’s Disease) is the only
clinically-approved glycosidase inhibitor. It is a D-glucose
analogue, which alters protein glycol processes within the
endoplasmic reticulum (ER) and inhibits the interactions
between folding glycoproteins and the ER chaperones cal-
nexin and calreticulin by alpha 1,2-glucosidase inhibition
[21,22]. The anti-viral effects of Miglustat have been well-
documented in mammalian cells. It changes the viral
envelope N-glycan composition and inhibits human im-
munodeficiency virus (HIV) entry (fusion) by a combined
effect of a reduction in virion GP120 content and a quali-
tative defect of GP120 shedding and GP41 exposure
[21,22]. For human hepatitis B virus (HBV), Miglustat pre-
vents the secretion of enveloped DNA and causes the
intracellular accumulation of excessive amounts of the en-
velope protein M [21].
EBOV GP proteins are heavily glycosylated and thus
should be very sensitive to Miglustat. This assumption
has been proved recently. Three derivates of Miglustat
showed significant in-vitro antiviral activities against
EBOV. Additionally, in a mouse model, high survival
rates (50-70%) were observed for the Miglustat-derivate-
treated animals [23]. Another recent study found that
the removal of all GP1 N-glycans outside the mucin-like
domain led to increases in protease sensitivity and anti-
body sensitivity, but also undesirably enhanced viral cell
entry (fusion) [24]. Therefore, I presume that Miglustat
may inhibit EBOV replication at the secretion or/and
envelopment steps, like the mechanism to HBV. Besides,
alteration to the EBOV GP glycan cap may also increase
viral sensitivity to neutralizing antibodies, stimulate
neutralizing antibody generation, and reduce the antibody-
dependent enhancement (ADE, mentioned above), which
would require further investigation (Figure 2 and Table 1).
NPC1 inhibitors
The endo/lysosomal cholesterol transporter protein
Niemann-Pick C1 (NPC1) is the intracellular receptor
to EBOV [25]. Cells defective for NPC1 function,
including primary fibroblasts derived from human
Niemann-Pick type C1 disease patients, are resistant to
infection by Ebola virus. The membrane fusion medi-
ated by EBOV glycoproteins and viral escape from the
vesicular compartment require the NPC1 protein. Inhib-
ition to NPC1 activity restricted the virus particles in cel-
lular vesicular compartments [25]. However, most NPC1
inhibitors are benzylpiperazine adamantane diamide deri-
vates; non-FDA-approved drugs [26]. In vitro screening of
readily available approved drugs showed that selective es-
trogen receptor modulators Clomiphene and Toremifene
are novel NPC1 inhibitors and act as potential inhibitors
of EBOV (Figure 2 and Table 1) [27,28]. Although thesurvival rate of Toremifene treatment was only 50% (90%
for Clomiphene), its effective concentration (2 μM) for
EBOV inhibition (over 50%) was much lower than that of
Clomiphene (10 μM) [28].
Besides Clomiphene and Toremifene, other cationic
amphiphiles, including Amiodarone, Dronedarone, and
Verapamil, also have been identified as potent inhibitors
of the entry of the EBOV in a NPC1-dependent fashion
[27,29]. However their effectiveness has only been
proven in in-vitro cell culture assays. There is also no
experimental evidence with living animals showing
their clinical effectiveness against EBOV infections
(Figure 2 and Table 1).
Other FDA-approved drugs
The Na+/K+ exchanger Amiloride inhibits virus uptake
by macropinocytosis [30,31], however, experimental evi-
dence with living animals is still lacking. Chloroquine in-
duces alkalinization of endosomes and prevents the acid
pH-dependent cleavage of Ebola virus GP by endosomal
proteases cathepsin B and L [32,33]. However, proteo-
lytic processing of the EBOV glycoprotein has been
demonstrated to not be critical for EBOV replication in
cell culture or nonhuman primates [34]. Favipiravir is a
broad-spectrum inhibitor of viral RNA polymerase that
is able to inhibit the replication of many RNA viruses.
However, the survival benefit by oral administration was
suboptimal in nonhuman primates. Only one of the
six animals tested survived [35]. Antioxidants (such as
N-acetylcysteine) could also be used to treat some
viral infections, however clinical trials of some antioxi-
dants in humans showed negative or ambiguous results
or insignificant benefits [36]. These drug candidates
for EBOV therapy have been recently summarized in a
review [37].
Drug effective concentration calculation for humans
Effective concentration calculation for Miglustat
25–75 mg/kg (50–150 μM/kg) Miglustat derivates at a
12-h interval were administrated for EBOV-infected
mice and survival rates were achieved [23]. These dos-
ages for mice are equal to 5.5-16.5 μM/kg (85–250 mg
each time, 170–500 mg/day) for humans. The standard
dosage for human Gaucher’s disease is 100 mg each, 3
times a day. And the maximum daily dose is 600 mg,
which is a little higher than above maximum dosage
(500 mg/day).
Furthermore, we should not only calculate the dosage
based on the body weight. Considering that endothelial
cells are the main targets of EBOV, the drug plasma con-
centration may merit more relevance. 10 μM or higher
concentration of Miglustat derivatives achieved inhib-
ition ratios of over 50% to Ebola virus [23]. A single dose
of 100 mg Miglustat administration resulted in the
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fluenced by food-intake). The plasma concentration
reaches a maximal value within 4 hours, while the half-
life time t1/2 is approximately 8 hours [38]. If 100 mg
Miglustat is administered every 4 hours, 6 times a day,
the plasma concentration would be stabilized at approxi-
mately 10 μM after 24 hours (contrastingly 12-hour inter-
val causes a large fluctuation; Figure 3). Sustained high
levels of Miglustat would inhibit viral replication persist-
ently, and its curative effect would be much better than
the situation with a large fluctuation, where the virus can
be replicated intermittently. The side-effects of Miglustat
include tremors, diarrhea, numbness, thrombocytopenia,
and some gastrointestinal reactions [38]. This low-dose,
short-interval drug-administration method may help to
reduce these adverse reactions. If 200 mg Miglustat is
administered every 8 hours, 3 times a day, the plasma con-
centration will be also higher than 10 μM after 24 hours
(Figure 3), however this dose could lead to increased ad-
verse reactions.Figure 3 Accumulative plasma levels of Miglustat and Clomiphene (Torem
Miglustat, three conditions are calculated: 250 mg each at an interval of 12
200 mg each at an interval of 8 hours (the maximum dosage and the no
(as suggested here). Plasma level of 250 mg/day Clomiphene (injection)
administration). Grey line indicates the supposed plasma level after sing
accumulative plasma levels of each drug. Purple line marks the concent
h, hours. d, days.Effective concentration calculation to Clomiphene and
Toremifene
A high level of 60 mg/kg (100 μM/kg, 2-day interval)
Clomiphene/Toremifene was used for EBOV-infected
mice and high survival rates were achieved [28]. This
dosage for mice is equal to 11 μM/kg (400 mg/day, 2-day
interval) for humans.
A single dose of 250 mg Clomiphene (the maximum
daily dose) administration resulted in a maximum plasma
concentration of about 3–4 μM. The minimum concen-
tration required for effective EBOV inhibition is 10 μM
[28]. However, Clomiphene is degradated very slowly (t1/2
is 5–7 days) [39], and therefore, a plasma concentration of
10 μM would be achieved after a second administration of
the drug (Figure 3).
This plasma concentration of Clomiphene can only be
achieved via intravenous injection. For Clomiphene, the
plasma concentration by oral administration is about
27–50 times lower than the plasma concentration by
intravenous injection [40]. In a mouse model, Clomipheneifene) of different dosages and administration intervals in primates: For
hours (equal to the dosage and the interval for the mouse model);
rmal interval for humans); 100 mg each at an interval of 4 hours
is approximately equal to that of 600 mg/day Toremifene (oral
le drug administration. Red line or blue line shows the calculated
ration for effective EBOV inhibition as indicated in cell culture assay.
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[28]. Considering that Clomiphene injection is not fre-
quently used and inconvenient for African patients, oral
administration of Toremifene could be adopted instead. A
plasma concentration of 600 mg Toremifene by oral ad-
ministration is approximately equal to the plasma concen-
tration of 250 mg Clomiphene by intravenous injection
(14 μM on days 4; Table 1 and Figure 3) [41]. The side-
effects of Toremifene include hidrosis, metrorrhagia,
pruritus, fatigue, dizziness, headache, depression, and
other neurological symptoms, which are less severe than
Clomiphene [39].
Suggestion of Miglustat and Toremifene combination
Here I suggest the combination of both Miglustat and
Toremifene to treat and possibly cure EBOV infection.
Miglustat works at the secretion/envelopment step [23],
while Toremifene functions at the entry/fusion step [28].
They act through different mechanisms and thus should
be used in combination. A single use of Miglustat cannot
inhibit virus replication significantly (50-70% survival rates
were observed for the Miglustat-derivate-treated animals,
but not for Miglustat itself ) [23]. While application of
Toremifene alone could neither alter GP glycosylation nor
excite neutralizing antibody generation, and therefore the
remnant virus cannot be cleared efficiently. Only through
this combination, the lethal EBOV infection may be
cured. Toremifene is a NPC1 inhibitor [27,28]. High
levels of NPC1 inhibitors may cause a symptom similar
to Niemann-Pick disease, due to NPC1-inhibition-induced
cholesterol and sphingomyelin accumulation [42]. Luckily,
Miglustat is supposed to alleviate Niemann-Pick neuro-
logical symptoms by inhibiting sphingomyelin synthesis
[43]. In other words, Miglustat may partly alleviate the
side-effects of Toremifene.
Disseminated intravascular coagulation and possible
treatment options
Disseminated intravascular coagulation (DIC)
Although endothelial cells are the targets of EBOV, the
vascular endothelium remains relatively intact even at
terminal stages of disease [44]. The hemorrhagic fever is
not the direct result of EBOV-induced cytolysis of endo-
thelial cells, and is likely triggered by some immune-
mediated mechanisms: The virus itself and its toxins
damage vascular endothelial cells, induce activator XII,
kallikrein, and bradykinin, further activating the coagula-
tion system [45]. Bradykinin also causes blood vessels to
dilate (vasodilation) and therefore may cause hypotension
and shock [46]. DIC is subsequently induced [47,48].
Prolonged prothrombin and partial thromboplastin
[45] suggest microcirculation disturbance and the exist-
ence of these micro-thrombi during EBOV-infection.
EBOV-infection also induces a dramatic rise in circulatingD-dimers [45], indicating hyperfibrinolysis. Thus, both an-
ticoagulants (heparin or protein C) and anti-fibrinolytic
drugs (tranexamic acid) should be used for DIC patients
to prevent later multiple organ failure [47,48].
Blood transfusion
Acute DIC develops into the consumptive and hypocoa-
gulable stage very quickly, accompanied by acidosis [47].
Mechanical injuries to red blood cells and hemolysis
subsequently cause hemoglobin release, while free heme
causes severe oxidative damage [47]. DIC patient need
fresh blood to supply erythrocytes, fibrinogen, and co-
agulation factors (including platelets). Moreover, blood
transfusion also helps to balance serum electrolytes and
reduce oxidative stress. The innate immune reactions
after EBOV infection have been characterized as a “cyto-
kine storm”. Great immunosuppression occurs later,
which is characterized by very low levels of circulating
cytokines produced by T lymphocytes and by massive
apoptosis of peripheral CD4 and CD8 lymphocytes [12].
Blood transfusion could supply these cytokines and T
lymphocytes and therefore enhance the patient’s im-
mune system.
Haptoglobin
Adverse clinical effects associated with excessive free
hemoglobin can be attributed to several specific struc-
tural and biochemical properties of the hemoglobin mol-
ecule, and are caused by the following four mutually
interacting mechanisms: (a) extravascular translocation
of hemoglobin, which is a principal requirement for
hemoglobin and hemin to be able to induce their ad-
verse reactions in tissues; (b) nitric oxide and oxidative
reactions; (c) release of free hemin; and (d) molecular-
signaling effects of hemin. Haptoglobin can neutralize
hemoglobin and hemin and scavenge nitric oxide and
physiologic oxidants, preventing hemolytic transfusion
reactions and hemolysis-induced acute renal failure
[49,50]. A human plasma-derived haptoglobin product
has been approved for clinical use in Japan since 1985.
The effective haptoglobin doses ranges from 3 g to > 20
g [50]. Haptoglobin may be very helpful for the late-
stage patients.
Conclusions and perspective clinical trials
Among the possible FDA-approved drugs to treat Ebola
virus infection, Miglustat, Clomiphene, and Toremifene
are the most promising, with preclinical evidence in liv-
ing animals. Three derivates of Miglustat showed signifi-
cant in vitro antiviral activities against EBOV. In a
mouse model, significant survival rates (50-70%) were
observed for their treatments. The survival rate of mice
was 50-90% after Clomiphene/Toremifene treatments.
However, the uptake efficiency of Clomiphene by oral
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Toremifene is recommended. Miglustat works at the
secretion/envelopment step, while Toremifene functions
at the entry/fusion step. They act through different
mechanisms and thus should be used in combination. A
Single dose of Miglustat cannot inhibit virus replication
significantly. Meanwhile, application of Toremifene alone
cannot initiate neutralizing antibody generation, and
therefore the remnant virus cannot be cleared efficiently.
Only through this combination, the lethal EBOV infection
may be cured.
The effective dosages of Miglustat and Toremifene for
mice were much higher than those clinically used for
humans. Here I put forward a hypothetical treatment
protocol with cumulative uses of both Miglustat and
Toremifene to control EBOV effectively and synergistic-
ally. A comprehensive treatment protocol to EBOV in-
fection is proposed (Table 2). Miglustat and Toremifene
are FDA-approved drugs with oral availability, good
safety, and tolerability profiles and a long history of use.
The oral availability of these drugs offers great utility in
the resource-constrained geographical regions where
outbreaks of EBOV infection occur. With the evidences
in animal experiments and the effective plasma concen-
tration calculated here, this treatment protocol may beTable 2 Suggested treatment protocol to EBOV infection
Stage Symptoms Sug








II. 4–5 days after onset Hematemesis and melena, injection
area bleeding, hemorrhinia, hemoptysis,





III. 6–7 days after onset Measles-like maculopapular rash at
shoulders, palms and feet, then spreading
throughout the body, desquamation






IV. 8–9 days after onset Possible kidney failure or liver failure,








Notes: (1) Miglustat and Toremifene should be used for patients in the latent period
Miglitol or other analogues without side chain alkylation [23]. (3) If 100 mg Miglusta
8 hours may be applied instead (as calculated in Figure 2). (4) Ebola infections prog
The low-dose, short-interval drug-administration method should not be applied for
because it may be not feasible on the large scale. Blood transfusion Tranexamic aci
Adequate heparin must be used before the application of anti-fibrinolytic drugs [47
body weight.ready for human clinical trials. However, given the con-
straints of the FDA animal rules and the World Health
Organization (WHO) guidance, studies in non-human
primates to assess this treatment strategy are usually re-
quired before the advancement to human clinical trials.
There needs to be some level of efficacy demonstrated
in non-human primates through an administration route
and dosages similar to those that would be used in
humans. Furthermore, with all combinational therapies,
there is a potential antagonistic interaction(s) and/or
potential increase in cytotoxicity or toxicity in the animal
model, which should be also clarified before entering hu-
man clinical trials. Miglustat is a D-glucose analogue,
while Toremifene is a cationic amphiphile (a dimethy-
lethanamine derivate with three benzene rings). Therefore,
there should be no direct interaction between the two
drugs. Nevertheless, considering the severity of the
current outbreak, I hope the treatment protocol could be
approved by the World Health Organization (WHO)
and applied to patients tentatively (phase I clinical trial).
Alternatively, tests in non-human primates should be
carried out immediately before the human trial.
Because of its high mortality rate and infectious na-
ture, EBOV usually causes psychological panic among
the patients and the public that is more serious than thegested drugs/treatments Matters needing attention
iglustat (100 mg each at an
val of 4 hours)
a,b) Until fully viral clearance. c)
If haemorrhage occurs, see
Stage II.
remifene (600 mg/day for 5
ecutive days, 2 days rest)
ater and electrolyte supply
iglustat (6 × 100 mg/day) a,b) Until fully viral clearance. c)
One or two more blood transfusions
in the later days, if symptoms persist.
If acute DIC occurs, see Stage III.
remifene (600 mg, 5 days)
0–400 ml blood transfusion
iglustat (6 × 100 mg/day) a,b) Until fully viral clearance. c) One
or two more blood transfusions. DIC
must be treated to prevent multiple
organ failures.
remifene (600 mg, 5 days)
0–800 ml blood transfusion
arin and tranexamic acid
be used)
iglustat (6 × 100 mg/day) a,b) Until fully viral clearance. c) One
or two more blood transfusions.
Massive blood transfusion or
hemodialysis may be adopted
if available.
remifene (600 mg, 5 days)
0 ml or more blood transfusion
arin and tranexamic acid should
sed)
20 g human plasma haptoglobin
ailable) [51]
upon diagnosis of EBOV infection. (2) Miglustat may not be replaced by
t at an interval of 4 hours is not feasible, 200 mg Miglustat at an interval of
ress very fast, thus the virus replication should be inhibited in the first time.
Toremifene (as calculated in Figure 2). (5) Blood transfusion is not obligatory,
d may be replaced by 4-aminomethyl benzoic acid or 6-amino acetic acid.
,48]. (6) Reduced dosages should be adopted for children according to their
Yuan Infectious Diseases of Poverty  (2015) 4:23 Page 9 of 10disease itself. In Africa, some EBOV patients refuse
treatment and some other patients are hidden by their
families, because of psychological panic [51]. However,
these actions have accelerated viral spread and made
epidemic prevention very difficult. Thus, if Miglustat
and Toremifene, two FDA-approved drugs, are effective
for humans, the panic may be eliminated and the current
outbreak may be better controlled, in addition to poten-
tially saving thousands of lives.
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